Platelets play a role in cancer metastasis by acting as a dynamic reservoir of effector molecules which facilitate tumour vascularisation, growth and metastasis. However, little information is available about the mechanism of tumour cell induced platelet secretion (TCIPS) or the molecular machinery by which effector molecules are released from platelets.
Introduction
There is increasing evidence supporting an association between cancer growth, metastasis and platelet secretion (1) (2) (3) (4) . An association between thrombocytosis and cancer death was first reported in 1872 by Reiss and colleagues (5) and brought to our attention again in 1964 (6) . Boneu et al., in 1984 (7) , first reported the presence of degranulated platelets, characterized by low levels of ADP and serotonin, in patients with malignant solid tumours, while others reported an inverse relationship between cancer prognosis and platelet count in patients (8) .
Later, Karpatkin et al. , demonstrated that many tumour cells could directly activate platelets (9) .
Platelet depletion in tumour bearing mice triggers intra-tumour haemorrhage which is rescued by platelet secretome (1) demonstrating a requirement for platelet secretion to stabilize angiogenesis in tumour metastases. Indeed, platelet α -granules contain large reservoirs of cytokines and growth factors, including transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF) (10) (11) , which are selectively released upon platelet activation (12) (13) . Consistent with a role of platelet secretion in tumour metastasis, TGF-β derived from platelet α -granules has been shown to profoundly impact tumour metastasis and survival by enhancing an epithelial mesenchymal-like transition (EMT) and
suppressing tumour cell NK-mediated lysis respectively (2) (3) . Moreover, platelet secretion in a tumorigenic micro-environment seems to differ materially from wound-induced platelet secretion. Battinelli and colleagues demonstrated the capability of cancer cells to provoke the preferential release of pro-angiogenic mediators from platelet α -granules (4) , creating a dynamic microenvironment favourable for their growth and survival. Although considerable progress has been made in understanding the role that platelet secretion plays in tumour metastasis, very little is known about the ability of cancer cells to induce platelet granule release. Moreover, the precise molecular mediators of this phenomenon remain unknown.
In the present study we had two specific objectives. Firstly, we aimed to investigate the ability of cancer cells to elicit platelet secretion using a pair of human prostate cancer cell lines, PC3 and its highly metastatic variant PC3M, a pair of breast cancer cell lines, MCF-7 (low metastatic) and MDA-MB-231 (high metastatic), and colorectal cancer cells Caco-2, whose ability to induce platelet activation in vitro has been well characterized (14) (15) .
Secondly, we sought to elucidate the molecular pathway(s) that mediate platelet activation in response to metastatic prostate cancer cells, PC3M, using a pharmacologic approach. In a context of molecular divergence we propose a novel role for platelet FcγRIIa and
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Material and Methods

Reagents
All reagents were purchased from Sigma Aldrich (Dublin, Ireland) unless otherwise indicated. Thrombin receptor activating peptide (TRAP) was obtained from Bachem (Merseyside, UK). CHRONO-LUME reagent and the Ristocetin Cofactor Assay were purchased from Chrono-log (Labmedics Limited, UK). SQ29548 was obtained from Enzo Life Sciences (UK). Aspirin, GF-109203X, AACOCF3, LY294, PF228, PP2, Piceatannol, U73122 and Wortmannin were purchased from Tocris Bioscience. Abciximab (ReoPro) was provided from Centocor/Lilly. The mAb IV.3 Fab fragment against the FcγRIIa was kindly provided by Prof. P. Newman (BloodCenter Wisconsin, US).
Tumour Cell Culture
Caco-2 cells, a human epithelial colorectal adenocarcinoma cell line, PC3M-luc and PC3, metastatic and non-metastatic human prostate cancer cells , were a generous gift from Prof.
Marek W. Radomsky (TCD, Dublin, Ireland) and Prof. Judy Harmey (RCSI, Dublin, Ireland), respectively. MCF-7 and MDA-MB-231 breast cancer cells were kindly provided by Dr. Ann Hopkins (Beaumont Hospital, Dublin, Ireland). Caco-2 cells were grown as previously described (15) . PC3M-luc and MCF-7 were grown in MEM supplemented with 10% of FBS.
PC3 were grown in RPMI 1640 with 10% FBS. MDA-MB-231 were grown in DMEM with 10% FBS. When confluent, cells were detached using Accutase(Sigma Aldrich, Ireland).
Preparation of Human and Mouse Washed Platelets
Human blood was drawn on the day of the experiment from healthy, drug-free volunteers into 1:9(v/v) sodium citrate anti-coagulant (3.15%) with informed consent, in accordance with the Declaration of Helsinki. Ethical approval was obtained from the RCSI ethics committee.
Washed platelet(WP) suspension (300x10 3 plts/μL) was prepared as previously described (16) .Mouse washed platelets were drawn and prepared as previously described (17) (18) .
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Platelet Aggregation Assay
Platelet aggregation was monitored at 37°C with continuous stirring in a PAP-4/8 aggregometer (Bio-Data Corporation, Horsham, PA). All aggregation experiments were measured against Tyrode's Buffer as the blank. Platelets (300x10 3 plts/μl) were aggregated in the presence of cancer cells for 30 minutes or twice the lag-time taken for the onset of aggregation response, whichever was longest. Where inhibitors were used, platelets were pre-incubated for 15 minutes at 37°C, 300rpm prior to commencement of aggregation. The data are expressed either as % of Aggregation or as the area under the aggregation curve (AUC). Data are normalized to the maximal aggregation achieved with each agonist. The effect of the treatment on platelet aggregation was expressed as the % of the control sample activated with agonist or tumour cells, alone. Control samples were incubated with the corresponding volume of buffer or with either 0.1% DMSO (MRS2395, MRS2179, Wortmannin, LY294, PP2, PF228, Bay-61, Piceatannol, U73122, GF-109203X) or ethanol (SQ29548 and AACOCF3) used as vehicle for the reported inhibitors.
The Platelet Dense-Granule Secretion Assay
Platelet ADP/ATP secretion (PAS) from dense-granules was assessed as previously described (19) (20) and monitored in parallel with platelet aggregation on the same donors.
Briefly, increasing(0.1-100x10 3 cells/ml) or maximum(100x10 3 cells/ml) concentration of cancer cells were dispensed in a final volume of 10 µl into different wells of a 96-well white plate(Sigma-Aldrich, Ireland) and 80 μl of WP were gently pipetted on top. TRAP (10μM) was used as positive control. Cancer cells were then allowed to activate platelets for maximum 30 minutes at 37°C under fast orbital shake. Finally, 10 μl of the detection reagent Chronolume were added to the wells and the sample luminescence was detected using a Wallac 1420 Multilabel Counter (Perkin Elmer). Where inhibitors were used, WP were pretreated as above (see Aggregation assay). Data are expressed as a percentage of a maximal response (% MaxPAS; AU=Arbitrary Unit) as for aggregation.
P-selectin exposure α
-granule release was measured by P-selectin exposure. Washed human platelets at 300x10 3 plts/μl were pre-incubated at 37°C, 300rpm for 10 minutes with 50μg/ml of the α IIb β 3 inhibitor abciximab (to prevent platelet aggregation) prior to conducting the test response.
Platelets were subsequently stimulated with either TRAP or tumour cells (100x10 3 cells/ml) For personal use only. on November 1, 2017. by guest www.bloodjournal.org From as outlined above. Following incubation, platelets were stained with PE mouse anti-human CD62P and analysed by flow cytometry (Becton Dickinson,CA,USA).
Cancer cell adhesion to platelets
Washed platelets (100x10 3 plts/μl) were co-incubated with cancer cell suspensions (10 6 cells/ml) at 37 °C for 10-20 minutes according to the cell line used. Adhered platelets were labelled with a fluoresceinated (FITC) antibody directed against glycoprotein Gp IIb (CD41a) for 15 minutes at room temperature. Fluorescence was determined as above.
Phosphorylation of integrin
The phosphorylatyion of β 3 -integrin was determined from a method adapted from Law et al (21) . Briefly, washed platelets were stimulated as above (see Aggregation Assay), separated by SDS-PAGE and immunoblotted for phospho-integrin β 3 (pY759.7A,Santa Cruz Biothecnology). After stripping equal loading was verified by immunoblotting with integrin β 3 antibody (Cell Signalling).
STATISTICAL ANALYSIS
Data was analysed using GraphPad PRISM 4.0 software (San Diego, CA, USA software).
Results are expressed as the mean± SEM. Analysis of means was performed with a twotailed Student's t-test. Differences were considered significant at P values less than 0.05.
RESULTS
Tumour cell induced physiological platelet aggregation
The ability of cancer cells to induce platelet aggregation was analyzed using Caco-2 human colorectal cancer cells, and 2 variants of a human prostate carcinoma: the metastatic PC3Mluc cells and their non-metastatic variant subline,PC3 (22) . Representative results for the aggregation of washed human platelets by cancer cells are shown in Figure 1A To address whether platelets could bind directly to the cancer cells, we quantitatively evaluated the association of the platelet-specific protein, CD41a, with the cancer cells following co-incubation. Flow cytometric analysis showed that PC3M, PC3 and Caco-2 cells are negative for CD41a expression. However, CD41a expression is associated with Caco-2 and PC3M cells, but not PC3, following pre-incubation with platelets ( Figure 1D ) providing compelling evidence that platelet aggregation-inducing cancer cells are physically interacting with platelets.
To verify that a physiological aggregation was occurring, the ristocetin cofactor assay was performed and PC3M-luc cells were assessed for their ability to agglutinate lyophilized platelets in the presence of vWF rich plasma. Importantly, no agglutination could be observed when lyophilized platelets were stimulated with prostate cancer cells (100x10 3 cells/ml) or TRAP (10μM) over a period of 30 minutes in the presence of vWF (Supplemental Data;Figure1A). All together these results confirmed that physiological aggregation, and not passive agglutination was being observed in response to cancer cells.
Tumour cell induced physiological platelet secretion
Since it has been previously shown that platelets are an important source of bioavailable VEGF (4) and TGFβ (3) and because evidence has been provided that platelet secretion is crucial for platelet regulation of tumour homeostasis (1) , the capability of tumour cells to induce platelet secretion in vitro was explored using a luminometric assay normally used to detect the platelet ATP/ADP secretion (PAS) by dense-granules (19) . TRAP ( Finally, to ascertain that a physiological secretion was occurring, the amount of cytoplasmic LDH released by PC3M-luc stimulated platelets was measured. As evident from Supplemental Figure1B, no LDH was detected after platelet activation with either TRAP (10μM) or maximal concentration of PC3M-luc cells, strongly confirming that physiological secretion, not passive lysis, was being observed.
PC3M induced platelet response is PAR-1, GpIb and thromboxane receptor independent
As outlined above, cancer cell induced platelet secretion is a primary event followed by brisk aggregation. However, the knowledge of the precise molecular mediators responsible for the platelet-tumour interaction remains unclear. In the present study we specifically explored the platelet pathways required by the PC3M cells that give rise to secretion and aggregation by targeting potential platelet receptors and downstream mediators with pharmacological inhibitors. In general, the concentration of pharmacological inhibitors and blocking antibodies were chosen with regard to previous platelet studies (23) (24) (25) . In addition, dose-response curves were generated for selective antagonists (Figure 3 ; Supplemental We next investigated whether glycoprotein Ib (GpIb), the well characterized thrombin and vWF receptor, played a role in TCIPS. For this purpose we used a range of antibodies targeting different motifs within the GpIb molecule (24) . Importantly, GpIb inhibition did not affect PC3M-luc induced platelet secretion (Supplemental Data; Figure 4 ).
Previously, a role for Thromboxane A 2 (TXA 2 ) receptor inhibitors in selectively ablating human osteogenic sarcoma (MG63) induced platelet aggregation in vitro was suggested (26) (27) . In contrast, recent studies, demonstrated the ineffectiveness of acetyl salicylic acid (ASA), a well known inhibitor of TXA 2 synthesis inhibitor, in reducing TCIPA in the presence of either breast cancer(MCF-7) or colon cancer cells(Caco-2) (15, 28) . We therefore evaluated the effects of modulators of TXA 2 on PC3M TCIPA and TCIPS. As evident in Figure3C There is strong evidence supporting a role for platelet adhesion molecules, such as α IIb β 3 , in tumour cell induced platelet activation (30) (31) (32) . Abxicimab(20μg/ml), a specific monoclonal blocking antibody targeting α IIbβ3 significantly inhibited platelet aggregation and secretion Figure 4D ). This result reinforces the hypothesis that α IIb β 3 is a crucial molecular mediator of platelet activation upon cancer cell stimulus (33) .
Intracellular molecular mediators of TCIPA/S are divergently activated: Role of PI3K, Src and FAK
PI3 and Src-kinases are downstream to a broad range of platelet and tumour cell pathways, whereas FAK plays a key role in mediating downstream signals from integrins and growth factor receptors (34) (35) (36) (37) . However, the role of these intracellular platelet molecular mediators in our studies strongly overlap with pathways known to be involved in accessory signalling pathways that utilize ITAM signalling motifs.
Dependence of cancer cell induced platelet response on FcγRIIa signalling pathway
Considering the role that platelets play in the innate immune response (38) Figure   6D ). This result therefore identifies a new platelet receptor that is selectively required in PC3-M cancer cell-stimulated platelets by a mechanism, to date, completely unknown.
Activation of human platelets by FcγRIIa is associated with rapid tyrosine phosphorylation
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DISCUSSION
Once in the bloodstream, cancer cells perturb the surrounding micro-environment, triggering abnormal platelet responses (5) (6) (42) (43) (44) , mediated by direct (3) or indirect interactions (4) .
Platelets can be aggregated in vitro and in vivo by various cancer cell lines (31) , a phenomenon described in 1968 as "Tumour Cell Induced Platelet Aggregation"(TCIPA) (8) .
Many factors are secreted by platelet granules in response to tumour cells, such as TGF-β and VEGF, that support the metastatic cascade and promote tumour vascularisation (3) (4) .
Kerr and colleagues showed that many tumour-secreted proteins are taken up and stored in platelets and specifically released at the metastatic sites (13) . However, while the ability of cancer cells to aggregate and cluster platelets around the tumour is supported by a large body of experimental and clinical data (32, (45) (46) , the role of cancer cells in promoting platelet secretion of pro-carcinogenic and thrombotic factors is poorly understood. In the present study we show that highly metastatic colorectal cancer cells (Caco-2), and a prostate A sustained α -granule release was also observed in response to all the cell lines tested. It is noteworthy that the non metastatic prostate cancer PC3 cells activated α -granule secretion with no effect on aggregation and dense-granules release suggesting that non-metastatic cancer cells can activate platelets without stimulating a pro-thrombotic response. A more precise interrogation of the comparative contents of the bioactive agents in the platelet α granule-releasate may allow a greater understanding of molecular events that ensue following activation of platelets with metastatic or non-metastatic cells. Evaluation of platelet secretion over time showed that Caco-2 and PC3M-luc cancer cells induced platelet ATP/ADP release earlier than aggregation. The aggregation was characterized by a distinct lag time which correlated with the cell's ability to induce TCIPS. Moreover, antagonism of platelet P2Y 12 receptors with MRS2395 or scavenging of released ADP with apyrase significantly attenuated aggregation, but not secretion responses. Thus, these results strongly imply that cancer cell-induced release of dense-granule ADP facilitates the induction of platelet aggregation and suggest that rapid dense granule secretion is the primary platelet activation pathway in response to cancer cells. If this is indeed the case, then we can expect that all inhibitors of the secretory pathway(s) will also have a downstream impact on the For personal use only. on November 1, 2017. by guest www.bloodjournal.org From platelet aggregation responses recorded. Thus, agents that inhibit platelet secretion of dense-granules will de-facto inhibit the dependent response, namely aggregation, which may result in reduced thrombotic complications in cancer patients.
We next explored the activity of a range of pharmacological inhibitors targeted at various platelet receptors and cytosolic signalling proteins. We were interested mainly in agents that inhibited both secretion, which we hypothesized to be a primary response, and aggregation, which would represent a secondary response. In this screen, inhibitors of Integrin α IIb β 3 , FAK, Syk kinase, and PKC showed significant effects on both TCIPS and TCIPA. These components have all previously been identified in association with each other in a platelet context.
FcγRIIa is an ITAM containing receptor used in platelets for immune-receptor signalling (47) .
The ITAM signalling motif is also found in other receptors in platelets, such as the collagen receptor complex GPVI-FcR γ chain, and the podoplanin receptor CLEC-2. More recently a role for podoplanin-CLEC-2 axis in mediating tumour metastasis has been identified (48) .
FcγRIIa directly interacts with Syk, activating PKC either directly (25) or via PLC activation (40) .
In our studies, FcγRIIa inhibition with the fab antibody IV.3 substantially blocked both platelet secretion and aggregation. Similarly, inhibition of the tyrosine kinase Syk reduced both TCIPS and TCIPA. Activation of Syk leads to phospholipase Cγ2(PLCγ2) phosphorylation and activation (48) (49) . PLCγ2 is a central enzyme in inducing the production of second messengers inositol(1,4,5)-trisphosphate(IP3) and diacylglycerol(DAG) leading to raised levels of intracellular calcium and activation of protein kinase C(PKC) which can positively regulate α -and dense-granule secretion in platelets as well as platelet aggregation (41, 50) .
Inhibition of PLC in our studies significantly reduced aggregation and secretion (Figure6)
indicating that an FcγRIIa-Syk-PLCγ signalling pathway is activated. In contrast, we observed that BAPTA, a calcium chelator, has no significant effect on platelet secretion responses, suggesting that calcium is not required. Importantly, inhibitors of PKC (GF109203X) demonstrated a potent dual inhibition of both TCIPS and TCIPA. Together, these data indicate that signalling for PC3M-luc mediated dense-granule secretion involves
FcγRIIa molecular components by engaging downstream signalling mechanisms including
Syk and that this event would be sufficient to initiate dense-granule secretion. Further studies will be necessary in order to identify the PKC isoform(s) activated during PC3M-luc induced platelet aggregation and secretion.
The discovery of FcγRIIa as an important mediator of both platelet aggregation and secretion in response to PC3M-luc make it a strong potential target for therapeutic
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From intervention. This raises the possibility of tumour cell induced platelet secretion (TCIPS) as a target for potential intervention in tumour angiogenesis and metastasis, and in tumour derived thrombosis. The inhibition of this platelet receptor, although not targeting the tumour cell itself, could potentially reduce metastasis and prevent thrombotic events associated with cancer without compromising the haemostatic functions of platelets.
The nature of the cancer cell ligand that stimulates platelet activation remains to be elucidated. Podoplanin is a recently-identified protein found on some cancer types that acts as ligand for CLEC-2, a platelet ITAM-containing receptor. However, podoplanin is not usually found on colon or prostate cancer (48) and we further confirmed this by flow cytometry analysis (Data not shown). In vivo, it is likely that anti-tumour antibodies could be inadvertent accessories in platelet responses, binding to FcyRIIa via their Fc portion and resulting in enhanced facilitation of tumour cell transport to a metastatic site instead of the intended immune-mediated elimination of a damaging invader cell. However, in the assays performed in this study, we utilized washed human platelets and washed human prostate cancer cells, so no exogenous antibodies are available for activation of platelets. Therefore, an alternative mode for the FcyRIIa receptor must be operating. Recently, in platelets, FcγRIIa has been identified as a transmembrane receptor responsible for mediating "outside-in" signaling through α IIb β 3 (51) . Of note, we have identified that, in addition to the Finally, it is noteworthy that platelet TXA 2 synthesis is a critical component of ADP-induced platelet activation. Aspirin, a potent inhibitor of platelet thromboxane production and a widely used anti-platelet agent, has demonstrable potential as an anti-neoplastic agent (52) .
In a large meta-analysis of >17,000 patients, daily usage of low-dose aspirin has been shown to reduce the incidence, growth and metastasis of a number of cancers in a period of 5-6 years (52) . This finding provides proof of principle for anti-platelet pharmacological intervention to specifically prevent cancer metastasis. Although our studies failed to demonstrate a significant effect of aspirin on TCIPA and TCIPS, a strong tendency towards inhibition was noted. Our data suggest that anti-platelet treatment with P2Y 12 inhibitors may provide a superior inhibition of platelet activation in response to tumour cells and this may have a therapeutic implication.
6
The cell numbers used in this study are admittedly in excess of numbers that might be found physiologically in circulating blood. Circulating tumour cell counts of >30/ml are routinely observed in prostate cancer patients (53) . The detection of circulating tumour cells (CTCs) in the blood and disseminated tumour cells (DTCs) in the bone marrow of cancer patients is associated with a poor prognosis (54) . Our study demonstrates that platelet activation can occur after a brief, but targeted, interaction with high numbers of cancer cells in vitro. The in vivo correlate of our study would allow for a longer interaction time with CTCs and a more targeted interaction with DTCs. Thus we believe that although the numbers of cancer cells used in our study is not physiological, the deductions made from such in vitro studies will have physiological relevance if time and opportunity are taken into account.
In conclusion, this work demonstrates for the first time, the capability of cancer cells to directly promote platelet secretion which is required to augment tumour-cell induced platelet aggregation. In addition, we have identified molecular mediators divergently activated in the aggregation and secretion responses (Figure7). Furthermore and most importantly, we recognize a novel essential role for FcγRIIa in prostate cancer cell induced platelet activation opening the door to novel anti-metastatic therapies.
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From 
Figure Legends
FIG. 2.Tumour cells induced platelet secretion (TCIPS) preceded aggregation. A-B:
Washed platelets (300x10 3 plts/μL) were stimulated with increasing concentration (0.1- 
